Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NHS England Tackles Use Of ‘Ineffective And Dangerous’ Medicines

Executive Summary

The National Health Service in England has drawn up a proposed list of “ineffective and dangerous” medicines that should not be routinely used in primary care, in a move to conserve resources and improve patient outcomes. They include products containing substances like fentanyl, tadalafil and trimipramine, as well as homeopathics and traditional herbal medicines.

You may also be interested in...



Crack-Down On Homeopathic Products Pushed By EU Science Advisory Council

European Academies Science Advisory Council urges “standardized, knowledge-based” regulatory framework for homeopathic products, similar to requirements for medicinal products in the EU. The umbrella organization representing 29 European scientific bodies says claims for the products are too often “implausible” and threaten consumer health.

Crack-Down On Homeopathic Products Pushed By EU Science Advisory Council

European Academies Science Advisory Council urges “standardized, knowledge-based” regulatory framework for homeopathic products, similar to requirements for medicinal products in the EU. The umbrella organization representing 29 European scientific bodies says claims for the products are too often “implausible” and threaten consumer health.

RECOVERY Coronavirus Study ‘Will Attract Global Players To UK’

A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.

Topics

UsernamePublicRestriction

Register

PS121316

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel